Ancient herb may tame inflammation after heart attack
NCT ID NCT07445581
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether Tanhuo decoction, a traditional herbal mixture, can reduce inflammation and prevent future heart or brain events in elderly patients who have had both a heart attack and hardened brain arteries. About 480 participants will take either the herbal drink or a placebo for one week, alongside standard heart medications. Researchers will track blood markers, heart function, and major events like strokes or heart attacks for up to a year.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Tanhuo decoction (herbal mixture)
- What this could lead to
- If it works, this could point toward a natural supplement to reduce inflammation and lower the risk of heart attacks or strokes in elderly patients.
- What could go wrong
- This is an early-stage trial with no phase, so results are uncertain. The herbal treatment is given for only 7 days, and long-term benefits are unknown. Side effects are not yet well-documented.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 480 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Feb 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
60 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Hemodynamic stability within 24 hours following treatment for acute coronary syndrome 2. A confirmed prior diagnosis of ischemic cerebrovascular disease, or the presence of intracranial or extracranial arterial stenosis ≥50%, as verified by carotid and cerebrovascular ultrasound after admission 3. Manifestations consistent with fire-heat syndrome, including tongue body appearance, tongue coating, stool characteristics, mental state, facial complexion, breathing pattern, presence of fever, pulse features, oral sensation, and urine properties. A total score of ≥7 points based on the weighted scoring system for each item indicates the presence of fire-heat syndrome. 4. Age ≥ 60 years old Exclusion Criteria: 1. Patients with persistent hemodynamic instability beyond 24 hours, or those with ACS-related hypotension (SBP \< 90 mmHg or DBP \< 60 mmHg), or requiring coronary artery bypass grafting based on coronary artery lesions 2. History of chronic heart failure due to any cause 3. History of ischemic stroke, peptic ulcer, active bleeding, or major surgery within the past 3 months 4. Hepatic or renal dysfunction, defined as ALT or AST levels \>5 times the upper limit of normal, or estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m² 5. Previous history of bronchial asthma 6. Platelet count \<80×10⁹/L or anemia (hemoglobin ≤100 g/L) 7. Contraindication or allergy to aspirin, clopidogrel, ticagrelor, or statins 8. History of malignant tumor 9. Known allergy to components of traditional Chinese medicine
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute coronary syndrome comorbid with cerebral atherosclerosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Xuanwu Hospital of Capital Medical University
Beijing, Beijing Municipality, 100032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.